Antibiotics, cytokines, and endotoxin: A complex and evolving relationship in Gram-negative sepsis

Scandinavian Journal of Infectious Diseases, Supplement

Volumn , Issue 101, 1996, Pages 9-13

  Horn, David L ^a   Opal, Steven M ^b,c   Lomastro, Elizabeth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE; ENDOTOXIN; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIOLYSIS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; PATHOPHYSIOLOGY; SEPSIS; HUMAN; PHYSIOLOGY; REVIEW; SECRETION;

ANTI-BACTERIAL AGENTS; CYTOKINES; ENDOTOXINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; SEPSIS;

EID: 0030300196     PISSN: 03008878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653-658, 1987
2. Hopkin BNA. Too rapid destruction of gram-negative organisms. Lancet 2: 603-604, 1977.
3. Shenep JL, Flynn PM, Barrelt FF, Stidham GL, Westenkirkner OF. Serial quantitation of endotoxaemia and bacteraemia during therapy for gram-negative bacterial sepsis. J Infect Dis 565-568, 1988.
4. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM H, Sibbald WJ. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644-1655, 1992.
5. Parillo, JE. Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471-1477, 1993.
6. Morrison DC, Danner RL, Dinarello CA, Munford RS, Natanson C, Pollack M, Spitzer JJ, Ulevitch RJ, Vogel SN, McSweegan E. Bacterial endotoxins and pathogenesis of Gram-negative infections: current status and future direction. J Endotoxin Res 1: 71-83, 1994.
7. Leeson MC, Fujihara Y, Morrison DC. Evidence for lipopolysaccharide (LPS) as the predominant proinflammatory mediator in supernatants of antibiotic-treated bacteria. Infect Immun 62: 4975-4980, 1994.
8. Leeson MC, Morrison DC. Induction of proinflammatory responses in human monocytes by particulate and soluble forms of lipopolysaccharide. Shock 2: 235-245, 1994.
9. Henson PM, Henson JE, Fittschen C, Bratton DL, Riches DWH. Degranulation and secretion by phagocytic cells, p. 511-541. In: JI Gallin, IM Goldstein, R Snyderman, eds. Inflammation. Raven Press, New York, 1992.
10. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharides (LPS) and LPS binding protein. Science 49: 1431-1433, 1990.
11. Kozin F, Cochrane CG. The contact activation system of plasma: biochemistry and pathophysiology, pp. 103-123. In: JI Gallin, IM Goldstein, R Snyderman, eds. Inflammation. Raven Press, New York, 1992.
12. Gallin JI, Goldstein IM, Snydennan R. Overview, pp. 1-5. In: JI Gallin, IM Goldstein, R. Snyderman, eds. Inflammation. Raven Press, New York, 1992.
13. Glauser MP, Zanetti G, Gaumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet 338: 732-736, 1991.
14. Hailman E, Lichenstein, US, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse A, Zuckowski MM, Wright SD. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 179: 269-277, 1994.
15. Lee J-D, Kravchenko V, Kirkland TN, Han J, Mackman N, Moriarty A, Leturcq D, Tobias PS, Ulevitch RJ. Glycosylphosphatidylinositol-anchored or integral membrane forms of CD14 mediate identical cellular responses to endotoxin. Proc Natl Acad Sci 90: 9930-9934, 1993.
16. Pugin J, Ulevitch RJ, Tobias PS. A critical role of monocytes and CD14 in endotoxin-induced endothelial cell activation. J Exp Med 178: 2193-2200, 1993.
17. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ. Structure and function of lipopolysaccharide binding protein. Science 249: 1429-1431, 1990.
18. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci 90: 12040-12044, 1993.
19. Harris HW, Grunfeld C, Feingold KR, Read JE, Kane JP, Jones AL, Eichbaum EB, Bland GF, Rapp JH. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 91: 1028-1034, 1993.
20. Hirata M, Shimomura Y, Yoshida M, Morgan JG, Palings I, Wilson D, Yen MH, Wright SC, Larrick JW. Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharideinhibitory activity. Infect Immun 62: 1421-1426, 1994.
21. Appelmelk BJ, An YJ, Thijs BJ, MacLaren DM, de Graff J. Recombinant human bactericidal/permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand. Infect Immun 62: 3564-3567, 1994.
22. Opal SM, Marra MN, McKelligan B, Fisher CJ, Palardy JE, Scott R. Relative concentrations of endogenous endotoxinbinding proteins in infected body fluids. Lancet 344: 429-431, 1994.
23. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 181: 1743-1754, 1995.
24. Goldie AS, Fearon KCH, Ross JA, Barclay R, Jackson RE, Grant IS, Ramsay G, Blyth AS, Howie JC. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 274: 172-177, 1995.